The US Food and Drug Administration (FDA) has approved Lannett’s abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.

Loxapine Capsules are therapeutically equivalent to Watson Pharmaceuticals’ Loxitane Capsules.

The company expects to start commercialising the product in the next few weeks.

Lannett president and CEO Arthur Bedrosian said they have now received five product approvals from the FDA over the last three months.